Evommune, Inc. (EVMN) Stock Analysis & Investment Frameworks
Evommune, Inc. (EVMN) stock analysis on Invetso. Review Evommune, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Evommune, Inc. Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Evommune, Inc. Key Financial Metrics
- Market Cap: $185.09M
- Revenue: $13.00M
- ROE: -62.63%
- ROIC: -35.66%
- Dividend Yield: N/A
About Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.